Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lurbinectedin |
Synonyms | |
Therapy Description |
Zepzelca (lurbinectedin) is an alkaloid analogue that binds to the minor groove of DNA, resulting in delayed cell cycle progression and cell death (PMID: 20977459). Zepzelca (lurbinectedin) is an FDA-approved chemotherapy agent (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lurbinectedin | Zepzelca | PM01183 | Chemotherapy - Alkylating 18 | Zepzelca (lurbinectedin) is an alkaloid analogue that binds to the minor groove of DNA, resulting in delayed cell cycle progression and cell death (PMID: 20977459). Zepzelca (lurbinectedin) is an FDA-approved chemotherapy agent (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05918640 | Phase Ib/II | Lurbinectedin | Lurbinectedin in FET-Fused Tumors (LiFFT) | Recruiting | USA | 0 |
NCT01525589 | Phase II | Lurbinectedin | A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer | Completed | USA | ESP | 0 |
NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Completed | USA | SWE | ITA | GBR | FRA | ESP | DEU | CHE | BEL | 0 |
NCT01405391 | Phase I | Lurbinectedin | Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks | Completed | USA | 0 |
NCT06203210 | Phase III | Ifinatamab deruxtecan Amrubicin Lurbinectedin Topotecan | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 5 |
NCT06681220 | Phase II | Lurbinectedin Niraparib + Temozolomide | Biomarker Directed Trial of Temozolomide and PARP Inhibition in Relapsed SCLC (Relapsed SCLC) | Not yet recruiting | USA | 0 |
NCT05740566 | Phase III | Lurbinectedin Topotecan Amrubicin Tarlatamab | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT06228066 | Phase II | Avelumab + Lurbinectedin Lurbinectedin | Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) | Recruiting | USA | 0 |
NCT06217536 | Phase Ib/II | Lurbinectedin | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | Withdrawn | 0 | |
NCT05734066 | Phase Ib/II | Lurbinectedin | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma (EMERGE 101) | Recruiting | USA | CAN | 0 |